DekaBank Deutsche Girozentrale Invests $143,000 in Hims & Hers Health, Inc. (NYSE:HIMS)

DekaBank Deutsche Girozentrale acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) during the second quarter, according to its most recent 13F filing with the SEC. The fund acquired 7,110 shares of the company’s stock, valued at approximately $143,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC lifted its stake in shares of Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares in the last quarter. Quest Partners LLC lifted its position in shares of Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after acquiring an additional 3,507 shares in the last quarter. Van ECK Associates Corp bought a new position in shares of Hims & Hers Health in the second quarter worth $111,000. Daiwa Securities Group Inc. purchased a new position in shares of Hims & Hers Health in the second quarter valued at $142,000. Finally, Meeder Asset Management Inc. purchased a new stake in Hims & Hers Health during the 2nd quarter worth about $153,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

HIMS stock opened at $16.30 on Friday. The company has a market capitalization of $3.50 billion, a PE ratio of -1,630.00 and a beta of 1.05. Hims & Hers Health, Inc. has a one year low of $5.65 and a one year high of $25.74. The company’s 50 day moving average price is $17.35 and its two-hundred day moving average price is $17.05.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. During the same period in the previous year, the firm posted ($0.03) earnings per share. The firm’s revenue for the quarter was up 51.8% on a year-over-year basis. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 17,303 shares of Hims & Hers Health stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $22.07, for a total value of $381,877.21. Following the transaction, the insider now directly owns 185,326 shares of the company’s stock, valued at approximately $4,090,144.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $20.75, for a total transaction of $3,919,426.00. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at $695,166.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Michael Chi sold 17,303 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $22.07, for a total value of $381,877.21. Following the transaction, the insider now directly owns 185,326 shares of the company’s stock, valued at approximately $4,090,144.82. The disclosure for this sale can be found here. Insiders sold 701,904 shares of company stock worth $12,349,805 in the last ninety days. 17.71% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on HIMS. Truist Financial lifted their target price on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, July 18th. Jefferies Financial Group upped their target price on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, June 27th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research report on Wednesday, August 7th. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Finally, TD Cowen upped their target price on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $19.86.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.